NEW BRUNSWICK (dpa-AFX) - Johnson & Johnson (JNJ) Tuesday reported positive results from a second interim analysis of the Phase 3 CARTITUDE-4 study evaluating Carvykti compared to standard therapies for the treatment of patients with relapsed or lenalidomide-refractory multiple myeloma after one prior line of therapy.
Results from the interim analysis showed a statistically significant and clinically meaningful improvement in overall survival (OS) for patients treated with Carvykti versus standard therapies, the company said in a statement. Further, safety data were consistent with the approved label.
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
© 2024 AFX News
